Document Detail


Pulmonary embolism.
MedLine Citation:
PMID:  20628658     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Pulmonary embolism remains a common and potentially preventable cause of death.
OBJECTIVE: This article reviews the epidemiology, clinical features, diagnostic process, and treatment of pulmonary embolism.
DISCUSSION: Well recognised risk factors include recent hospitalisation, other causes of immobilisation, cancer, and oestrogen exposure. Diagnostic algorithms for pulmonary embolism that incorporate assessment of pretest probability and D-dimer testing have been developed to limit the need for diagnostic imaging. Anticoagulation should be administered promptly to all patients with pulmonary embolism with low molecular weight heparin being the initial anticoagulant of choice, although thrombolysis is indicated for patients presenting with haemodynamic compromise. Following initial anticoagulation warfarin therapy should be continued for a minimum of 3 months. Long term anticoagulation with warfarin should be considered in patients with unprovoked pulmonary embolism, due to an increased risk of recurrence after ceasing anticoagulation. The availability of new anticoagulants is likely to significantly impact on the treatment of patients with pulmonary embolism, although the exact role of these drugs is still to be defined.
Authors:
Simon McRae
Related Documents :
2500388 - Thrombolytic treatment of acute pulmonary embolism.
15222648 - Dvt and pulmonary embolism: part i. diagnosis.
3195848 - A retrospective analysis of inferior vena caval filtration for prevention of pulmonary ...
10811518 - The friday afternoon pulmonary angiogram: temporal relationship between onset of sympto...
8759208 - Scalp necrosis in temporal (giant cell) arteritis:implications for the dermatologic sur...
15547658 - Salmonella aortic aneurysm: suggestions for diagnosis and therapy based on personal exp...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Australian family physician     Volume:  39     ISSN:  0300-8495     ISO Abbreviation:  Aust Fam Physician     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-14     Completed Date:  2011-03-07     Revised Date:  2012-09-18    
Medline Journal Info:
Nlm Unique ID:  0326701     Medline TA:  Aust Fam Physician     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  462-6     Citation Subset:  IM    
Affiliation:
Department of Haematology, South Australia Pathology, Royal Adelaide Hospital, South Australia. simon.mcrae@health.sa.gov.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms
Anticoagulants / therapeutic use
Antifibrinolytic Agents / therapeutic use
Australia
Fibrin / metabolism
Fibrin Fibrinogen Degradation Products / analysis
Fibrinolytic Agents / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Pulmonary Embolism / diagnosis*,  drug therapy,  etiology
Risk Assessment
Risk Factors
Venous Thromboembolism / diagnosis*,  drug therapy,  etiology
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Antifibrinolytic Agents; 0/Fibrin Fibrinogen Degradation Products; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/fibrin fragment D; 9001-31-4/Fibrin
Comments/Corrections
Comment In:
Aust Fam Physician. 2011 Jan-Feb;40(1-2):9-10; author reply 10   [PMID:  21394938 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Atrial fibrillation--changes 2000 to 2009.
Next Document:  Deep vein thrombosis--risks and diagnosis.